Form 4: Denali Therapeutics Director Equity Grant Disclosure

Director Timothy Van Hauwermeiren received an equity grant of 6,408 RSUs and 19,226 stock options from Denali Therapeutics.

Summary

• Director Timothy Van Hauwermeiren was granted 6,408 Restricted Stock Units (RSUs) on June 3, 2026.
• The director also received a stock option grant for 19,226 shares with an exercise price of $19.66.
• Both the RSUs and the stock options are scheduled to vest fully on the earlier of the one-year anniversary of the grant or the day before the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new equity grants results in minor dilution to existing shareholders.

Risks

• Potential for future dilution if additional equity-based compensation is issued to directors and employees.

Future Outlook

The equity grants are subject to standard one-year vesting schedules, aligning director retention with the company's upcoming annual meeting cycle.

Industry Context

StockSavvy.ai notes that standard annual equity grants for board members in the biotechnology sector are common practice to ensure leadership retention and alignment with corporate performance milestones.

Comparison to Industry Standards

• The use of a one-year cliff vesting schedule for director equity is consistent with standard corporate governance practices for mid-cap biotech firms.
• The grant size is typical for non-employee director compensation packages in the life sciences industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity instruments.

Next Steps

• Vesting of the RSUs and stock options on the earlier of the one-year anniversary or the day before the next annual meeting.

Key Dates

Keywords

Denali Therapeutics, DNLI, Director Compensation, Equity Grant, Insider Transaction, Biotech